The Nifty Pharma index declined 2.67% after US President Donald Trump announced a 100% tariff on the sector, affecting Indian pharma stocks like Cipla, Biocon, and Lupin.
Amitabh Kant, former NITI Aayog CEO, emphasizes the importance of standing firm against US tariff pressure, highlighting the need for radical economic reforms in India.
Amitabh Kant, former NITI Aayog CEO, emphasizes the importance of India standing its ground against US tariff pressure, citing the need for a long-term, mutually productive partnership.